Johnson & Johnson's financial condition is stable, and Standard and Poor's has removed the downgrade warning.

Credit rating agency S&P Global, Inc. stated on Friday that Johnson & Johnson (JNJ.US) is no longer at risk of a credit downgrade. S&P has removed Johnson & Johnson from its watchlist for a downgrade, citing the company's "very conservative financial policies". S&P noted that Johnson & Johnson's department for developing new disease treatments and medical technologies has achieved stable sales growth, and the likelihood of significant cash outflows in the coming years from talcum powder-related lawsuits is low. Reportedly, S&P has given Johnson & Johnson the highest credit rating of "AAA", making it one of the few companies with the highest credit rating. In January of this year, S&P placed Johnson & Johnson on its credit watchlist with a negative outlook, mainly due to the company's almost $15 billion acquisition of mental illness drug developer Intra-Cellular Therapies. S&P believes that this acquisition will increase Johnson & Johnson's adjusted leverage to around 1.4 times, exceeding the 1 times downgrade trigger for S&P ratings.